Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

Age-related macular degeneration ... Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST, President Oh Sang-Rok) has developed a new therapeutic agent ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

A clever new set of glasses may offer new hope to people with macular degeneration. By copying the structure of a fly's eyes, the specs are claimed to "fill in" the missing section of the wearer's ...